Q3 EPS Estimate for Tonix Pharmaceuticals Lowered by Analyst

Key Points

• Noble Financial has downgraded its Q3 2025 earnings estimate for Tonix Pharmaceuticals, projecting a larger loss of ($3.93) per share, compared to the earlier estimate of ($2.99).
• Tonix Pharmaceuticals recently reported earnings that missed analyst expectations, showing a loss of ($3.86) per share against a consensus estimate of ($3.10).
• The stock has seen significant volatility, with a 12-month price range between $6.76 and $130.00, and recently traded down by 3.2%.

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Free Report) - Investment analysts at Noble Financial dropped their Q3 2025 earnings estimates for shares of Tonix Pharmaceuticals in a report released on Wednesday, August 13th. Noble Financial analyst R. Leboyer now anticipates that the company will earn ($3.93) per share for the quarter, down from their prior forecast of ($2.99). The consensus estimate for Tonix Pharmaceuticals' current full-year earnings is ($1,762.50) per share. Noble Financial also issued estimates for Tonix Pharmaceuticals' Q4 2025 earnings at ($4.44) EPS, FY2025 earnings at ($14.95) EPS, Q1 2026 earnings at ($3.16) EPS, Q2 2026 earnings at ($2.73) EPS, Q3 2026 earnings at ($2.29) EPS, Q4 2026 earnings at ($1.56) EPS and FY2026 earnings at ($9.74) EPS.

Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) last released its quarterly earnings data on Monday, August 11th. The company reported ($3.86) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($3.10) by ($0.76). The firm had revenue of $2.00 million during the quarter, compared to analysts' expectations of $2.60 million. Tonix Pharmaceuticals had a negative net margin of 828.22% and a negative return on equity of 57.93%.

TNXP has been the topic of several other reports. Wall Street Zen raised Tonix Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Saturday, June 7th. Alliance Global Partners reiterated a "buy" rating on shares of Tonix Pharmaceuticals in a report on Tuesday, June 3rd. Two analysts have rated the stock with a Buy rating, According to MarketBeat, the stock has a consensus rating of "Buy" and a consensus price target of $70.00.

Tonix Pharmaceuticals Price Performance

NASDAQ:TNXP traded down $0.5350 during mid-day trading on Friday, reaching $35.9950. 974,484 shares of the company's stock traded hands, compared to its average volume of 1,401,315. The company has a 50 day moving average price of $41.37 and a 200-day moving average price of $27.22. The firm has a market capitalization of $315.68 million, a price-to-earnings ratio of -0.91 and a beta of 1.70. Tonix Pharmaceuticals has a 12-month low of $6.76 and a 12-month high of $130.00.

Hedge Funds Weigh In On Tonix Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Legal & General Group Plc bought a new stake in shares of Tonix Pharmaceuticals in the 2nd quarter worth $25,000. Ameritas Investment Partners Inc. purchased a new stake in shares of Tonix Pharmaceuticals during the second quarter valued at $28,000. Police & Firemen s Retirement System of New Jersey bought a new stake in Tonix Pharmaceuticals in the 2nd quarter worth about $62,000. BNP Paribas Financial Markets purchased a new position in Tonix Pharmaceuticals in the 2nd quarter worth about $65,000. Finally, New York State Common Retirement Fund purchased a new position in Tonix Pharmaceuticals in the 2nd quarter worth about $104,000. 82.26% of the stock is owned by institutional investors.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.